Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Hemorrhage 13 Neoplasms 7 Leiomyoma 6 Breast Neoplasms 6 Hematologic Neoplasms 4 Thrombocytopenia 3 Postoperative Hemorrhage 3 Meningioma 3 Urinary Bladder Neoplasms 2 Stomach Neoplasms 2 Seroma 2 Prostatic Neoplasms 2 Ovarian Neoplasms 2 Myofibroma 2 Head and Neck Neoplasms 2 Colonic Neoplasms 2 Brain Neoplasms 2 Bone Neoplasms 2 Blood Loss, Surgical 2 Wrist Fractures 1 Urologic Diseases 1 Urinary Retention 1 Thromboembolism 1 Skin Neoplasms 1 Seizures 1 Sarcoma 1 Recurrence 1 Postoperative Complications 1 Polyposis, Gastric 1 Pituitary Neoplasms 1

Interventions

pembrolizumab 287 Nivolumab 258 Ipilimumab 236 Cyclophosphamide 135 aldesleukin 134 Interleukin-2 104 Temozolomide 75 Dacarbazine 74 trametinib 70 Vemurafenib 69 fludarabine 68 dabrafenib 65 fludarabine phosphate 62 sargramostim 44 binimetinib 44 Radiosurgery 44 Biopsy 43 Paclitaxel 42 Bevacizumab 42 incomplete Freund's adjuvant 39 encorafenib 37 Radiotherapy 36 Cisplatin 36 CTLA-4 Antigen 36 atezolizumab 35 Carboplatin 35 Magnetic Resonance Spectroscopy 33 cobimetinib 32 Specimen Handling 31 Introns 30

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Melanoma × Tranexamic Acid × Clear all

NCT05899465 2025-03-18

PRIME

University of Aarhus

Phase 3 Recruiting

Melanoma, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡